DARZALEX® + Pomalyst® (pomalidomide) + dexamethasone
A multicenter, open-label phase 1b study1,2
Patients had received prior treatment with a proteasome inhibitor (PI) and an immunomodulatory agent1
- This trial included 103 patients who received DARZALEX® 16 mg/kg in combination with Pd and were treated with pre- and post-infusion medications. Patients were treated until disease progression or unacceptable toxicity1,3
- Patients had a median of 4 prior lines of therapy1
- Of the patients who were tested for cytogenetics, 74.7% were standard risk and 25.3% were high risk3
Patients were refractory to prior therapies1*
- 89% to lenalidomide
- 71% to bortezomib
- 64% to bortezomib and lenalidomide
*Plesase note that this is not a full list of prior therapies.
Patient Characteristics
ECOG=Eastern Cooperative Oncology Group.